Net sales declined 8% year-over-year to 13.1 MSEK, but operating losses narrowed due to cost savings and improved efficiency. Strategic partnerships and regulatory approvals support future growth, with recurring revenue from cNeuro rising and a strong cash position after a successful rights issue.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.